302 related articles for article (PubMed ID: 24361860)
21. Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS.
Zheng Y; Lui G; Boujaafar S; Aboura R; Bouazza N; Foissac F; Treluyer JM; Benaboud S; Hirt D; Gana I
J Pharm Biomed Anal; 2021 Mar; 196():113923. PubMed ID: 33571728
[TBL] [Abstract][Full Text] [Related]
22. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.
Quaranta S; Woloch C; Paccou A; Giocanti M; Solas C; Lacarelle B
Ther Drug Monit; 2009 Dec; 31(6):695-702. PubMed ID: 19865000
[TBL] [Abstract][Full Text] [Related]
23. HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in human plasma.
Zheng Y; Aboura R; Boujaafar S; Lui G; Hirt D; Bouazza N; Foissac F; Treluyer JM; Benaboud S; Gana I
J Pharm Biomed Anal; 2020 Apr; 182():113119. PubMed ID: 32004775
[TBL] [Abstract][Full Text] [Related]
24. A highly sensitive and selective LC-MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies.
Kandoussi H; Jiang H; Zeng J; Zheng N; Kadiyala P; Eley T; He B; Garimella T; Demers R; Cojocaru L; Aubry AF; Arnold ME
J Pharm Biomed Anal; 2016 Feb; 119():145-51. PubMed ID: 26683987
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.
Prathipati PK; Mandal S; Destache CJ
J Pharm Biomed Anal; 2016 Sep; 129():473-481. PubMed ID: 27497648
[TBL] [Abstract][Full Text] [Related]
26. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.
Adams JL; Patterson KB; Prince HM; Sykes C; Greener BN; Dumond JB; Kashuba AD
Antivir Ther; 2013; 18(8):1005-13. PubMed ID: 23899439
[TBL] [Abstract][Full Text] [Related]
27. Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate.
Ryan KJ; Guimbellot JS; Dowell AE; Reed-Walker KD; Kerstner-Wood CD; Anderson JD; Liu Z; Acosta EP
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Dec; 1213():123518. PubMed ID: 36371965
[TBL] [Abstract][Full Text] [Related]
28. Validation and Clinical Application of a Liquid Chromatography-Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots.
Akinloye A; Eniayewu O; Adeagbo B; Bolaji O; Olagunju A
Ther Drug Monit; 2022 Jun; 44(3):430-437. PubMed ID: 34629444
[TBL] [Abstract][Full Text] [Related]
29. A validated UPLC-MS/MS method for the determination of CX3002 in human plasma and its application to a pharmacokinetic study.
Hu X; Xu Y; Chen J; Shen Y; Yang D; Hu Y; Jiang B; Lou H; Ruan Z
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1183():122954. PubMed ID: 34628186
[TBL] [Abstract][Full Text] [Related]
30. A simple assay for the simultaneous determination of human plasma albendazole and albendazole sulfoxide levels by high performance liquid chromatography in tandem mass spectrometry with solid-phase extraction.
Wojnicz A; Cabaleiro-Ocampo T; Román-Martínez M; Ochoa-Mazarro D; Abad-Santos F; Ruiz-Nuño A
Clin Chim Acta; 2013 Nov; 426():58-63. PubMed ID: 24008168
[TBL] [Abstract][Full Text] [Related]
31. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
32. Quantification of nine antiretroviral drugs in cerebrospinal fluid: An approach to overcome sample collection tube adsorption.
Mykris TM; Weinhold J; Winchester LC; Scarsi KK; Fletcher CV; Podany AT; Avedissian SN
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Jul; 1227():123810. PubMed ID: 37429153
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a liquid chromatography-MS/MS method for simultaneous quantification of tenofovir and efavirenz in biological tissues and fluids.
Barreiros L; Cunha-Reis C; Silva EMP; Carvalho JRB; das Neves J; Sarmento B; Segundo MA
J Pharm Biomed Anal; 2017 Mar; 136():120-125. PubMed ID: 28073073
[TBL] [Abstract][Full Text] [Related]
34. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.
Greener BN; Patterson KB; Prince HM; Sykes CS; Adams JL; Dumond JB; Shaheen NJ; Madanick RD; Dellon ES; Cohen MS; Kashuba AD
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):39-44. PubMed ID: 23945251
[TBL] [Abstract][Full Text] [Related]
35. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.
Podany AT; Scarsi KK; Fletcher CV
Clin Pharmacokinet; 2017 Jan; 56(1):25-40. PubMed ID: 27317415
[TBL] [Abstract][Full Text] [Related]
36. Quantitative bioanalytical assay for the human epidermal growth factor receptor (HER) inhibitor dacomitinib in rat plasma by UPLC-MS/MS.
Qiu X; Lin Q; Ning Z; Qian X; Li P; Ye L; Xie S
J Pharm Biomed Anal; 2019 Mar; 166():66-70. PubMed ID: 30612075
[TBL] [Abstract][Full Text] [Related]
37. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
[TBL] [Abstract][Full Text] [Related]
38. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1.
Yagura H; Watanabe D; Kushida H; Tomishima K; Togami H; Hirano A; Takahashi M; Hirota K; Ikuma M; Kasai D; Nishida Y; Yoshino M; Yamazaki K; Uehira T; Shirasaka T
BMC Infect Dis; 2017 Sep; 17(1):622. PubMed ID: 28915895
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous determination of Guanfu base G and its active metabolites by UPLC-MS/MS in rat plasma and its application to a pharmacokinetic study.
Zhang L; Wang A; Wang X; Zhang Y; Li X; Liu P
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Apr; 957():1-6. PubMed ID: 24636893
[TBL] [Abstract][Full Text] [Related]
40. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.
D'Avolio A; Simiele M; Siccardi M; Baietto L; Sciandra M; Oddone V; Stefani FR; Agati S; Cusato J; Bonora S; Di Perri G
J Pharm Biomed Anal; 2011 Mar; 54(4):779-88. PubMed ID: 21071165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
